Lancet
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.
Randomised trial in 1,152 peopleRetatrutide